ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 033

Kawasaki Disease (KD) Criteria Fulfillment and Associated Outcomes in Multisystem Inflammatory Syndrome in Children (MIS-C)

Lyndsey Cole, Marsha Anderson, Heather Heizer, Michelle Hite, Christina Osborne, Samuel Dominguez and Pei-Ni Jone, University of Colorado School of Medicine, Denver, CO

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: Diagnostic criteria, Miscellaneous Rheumatic and Inflammatory Diseases, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, March 31, 2023

Title: Poster Breakout 5 - Autoinflammatory/Vasculitis: STAT3, NLRP3, KD and MIS-C

Session Type: Breakout Session

Session Time: 4:30PM-5:00PM

Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a hyperinflammatory illness associated with SARS-CoV-2 infection and has overlapping features with Kawasaki Disease (KD). The objective was to describe fulfillment of complete and incomplete KD criteria among patients with MIS-C, and to compare features at admission and clinical outcomes among patients with MIS-C who did or did not meet KD criteria.

Methods: Single pediatric hospital retrospective chart review of all patients who met U.S. Centers for Disease Control and Prevention (CDC) MIS-C criteria and received treatment between April 2020 to February 2021.

Results: 79 patients with MIS-C were identified. 55/79 patients (70%) met criteria for KD at admission (n=26) or later in the hospitalization (n=29). Of those, 28/55 (51%) met criteria for complete KD and 27/55 (49%) for incomplete KD. Patients meeting KD criteria at admission presented later (mean day 7 vs. 5, P< 0.001) and were more likely to have rash, mucous membrane changes, conjunctivitis, extremity changes, and hypoalbuminemia at admission compared to those who did not (P=0.01, 0.005, < 0.001, 0.008, and < 0.001, respectively). There were no differences in coronary artery lesions (CAL), left ventricular (LV) dysfunction, respiratory failure, or needs for intensive care, vasoactive medications, or second- or third-line MIS-C therapy. Patients who did not meet KD criteria at admission but did later in the hospitalization were more likely to have rash, hypoalbuminemia, and elevated alanine transaminase at admission (P=0.05, 0.007, and < 0.001, respectively), respiratory failure (P=0.02) and had greater need for intensive care, vasoactive medications, and second- and third-line therapy than patients never meeting KD criteria (P< 0.001, < 0.001, 0.001, and 0.005, respectively). There were no differences in CAL or LV dysfunction.

Conclusion: Most patients with MIS-C met criteria for KD by time of hospital discharge. Fulfillment of KD criteria at admission was not associated with changes in MIS-C patient outcomes, though fulfillment of KD criteria later during hospitalization was associated with greater need for intensive care, vasoactive medications, and second- and third-line MIS-C therapy. KD criteria fulfillment in patients with MIS-C at any timepoint was not associated with increased risk of CAL or LV dysfunction. Further investigation is needed to understand how pathophysiology of MIS-C compares to KD and if presence of KD features can help predict outcomes in MIS-C.

Supporting image 1Figure 1: Patients with MIS-C Meeting KD Criteria

Supporting image 2Table 1: Characteristics and Outcomes Among Patients with MIS-C Based on KD Criteria


Disclosures: L. Cole: None; M. Anderson: None; H. Heizer: None; M. Hite: None; C. Osborne: Biofire, 5; S. Dominguez: Biofire, 2, 5, Karius, 2, Pfizer, 5; P. Jone: None.

To cite this abstract in AMA style:

Cole L, Anderson M, Heizer H, Hite M, Osborne C, Dominguez S, Jone P. Kawasaki Disease (KD) Criteria Fulfillment and Associated Outcomes in Multisystem Inflammatory Syndrome in Children (MIS-C) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/kawasaki-disease-kd-criteria-fulfillment-and-associated-outcomes-in-multisystem-inflammatory-syndrome-in-children-mis-c/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/kawasaki-disease-kd-criteria-fulfillment-and-associated-outcomes-in-multisystem-inflammatory-syndrome-in-children-mis-c/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology